## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($86.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen**
- Source: Benzinga | 20251216T171052 | Bullish | Relevance: 100%
- AstraZeneca (NASDAQ: AZN) received FDA approval for Enhertu, in combination with pertuzumab, for first-line treatment of HER2-positive breast cancer, based on positive DESTINY-Breast09 trial results. This approval triggers a $150 million milestone payment to Daiichi Sankyo. Additionally, the European Commission approved AstraZeneca's Saphnelo for subcutaneous self-administration in systemic lupus erythematosus, with AstraZeneca paying a royalty to Bristol-Myers Squibb & Co (NYSE: BMY) on sales.

**2. AstraZeneca PLC - Enhertu approved in US for 1L HER2+ metastatic BC**
- Source: Research Tree | 20251216T121052 | Bullish | Relevance: 100%
- AstraZeneca and Daiichi Sankyo's Enhertu, in combination with pertuzumab, has received US FDA approval for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. This approval, based on the DESTINY-Breast09 Phase III trial, marks the first new treatment in a decade for this indication, demonstrating significantly improved progression-free survival. The combination reduced the risk of disease progression or death by 44% compared to the previous standard of care (THP), with a median progression-free survival exceeding three years.

**3. AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval**
- Source: Seeking Alpha | 20251215T220918 | Bullish | Relevance: 100%
- The U.S. FDA has approved a combination therapy of AstraZeneca/Daiichi Sankyo's Enhertu and Roche-owned Genentech's Perjeta for the first-line treatment of HER2-positive breast cancer. This approval is based on phase 3 data indicating that the combination significantly reduced disease progression or death.

**4. AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment**
- Source: Reuters | 20251216T010918 | Bullish | Relevance: 100%
- The U.S. Food and Drug Administration (FDA) has approved Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, for first-line treatment in combination with Roche's Perjeta. This expanded approval targets adults with advanced HER2-positive breast cancer, based on study results showing a significant extension in progression-free survival. The decision moves Enhertu beyond its initial third-line treatment approval in 2019.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $278.6B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.4 |
| Current P/E | 19.6 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.9% to 2.1% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.07% (CS: 45) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.166x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $89.86
- **Stop Loss:** $86.78 (3.4% risk)
- **Target:** $92.94 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 350
- **Position Value:** $31,451.00
- **Portfolio %:** 31.45%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*